Alnylam Pharmaceuticals, Inc. [NASDAQ:ALNY]: Analyst Rating and Earnings
Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Alnylam Pharmaceuticals, Inc. [ALNY], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of December. On average, stock market experts give ALNY an Outperform rating. The average 12-month price forecast for this stock is $115.33, with the high estimate being $160.00, the low estimate being $62.00 and the median estimate amounting to $113.50. This is compared to its latest closing price of $89.16.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Alnylam Pharmaceuticals, Inc. [ALNY] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 1.94.
Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Thu 14 Feb (In 33 Days).
Fundamental Analysis of Alnylam Pharmaceuticals, Inc. [ALNY]
Now let’s turn to look at profitability: with a current Operating Margin for Alnylam Pharmaceuticals, Inc. [ALNY] sitting at -556.20. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -34.89, and its Return on Invested Capital has reached -27.80%. Its Return on Equity is -36.54, and its Return on Assets is -30.14. These metrics suggest that this Alnylam Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Alnylam Pharmaceuticals, Inc. [ALNY] has generated a Total Debt to Total Equity ratio of 1.70. Similarly, its Total Debt to Total Capital is 1.67, while its Total Debt to Total Assets stands at 1.50. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 1.70, and its Long-Term Debt to Total Capital is 1.67. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is -12.20. The Enterprise Value to Sales for this firm is now 64.67, and its Total Debt to Enterprise Value stands at 0.00. Alnylam Pharmaceuticals, Inc. [ALNY] has a Price to Book Ratio of 7.17.
Shifting the focus to workforce efficiency, Alnylam Pharmaceuticals, Inc. [ALNY] earns $120,043 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.14 and its Total Asset Turnover is 0.06. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 12.23 and its Current Ratio is 12.23. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Alnylam Pharmaceuticals, Inc. [ALNY] has 97.75M shares outstanding, amounting to a total market cap of $8.71B. Its stock price has been found in the range of 60.27 to 153.99. At its current price, it has moved by -42.12% from its 52-week high, and it has moved 47.87% from its 52-week low.
This stock’s Beta value is currently 2.56, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 70.66. This RSI suggests that Alnylam Pharmaceuticals, Inc. is currently Overbought.
Conclusion: Is Alnylam Pharmaceuticals, Inc. [ALNY] a Reliable Buy?
Shares of Alnylam Pharmaceuticals, Inc. [ALNY], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.